Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012

This article was originally published in The Gray Sheet

Executive Summary

Thoratec plans to start a clinical trial at the end of 2012 for its next-generation HeartMate III left ventricular assist device with a magnetically levitated rotor designed to help reduce the risk of pump-related clots, bleeding and strokes.

You may also be interested in...

Thoratec Looks To Next-Generation LVADs To Revive Sinking Sales

Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.

Thoratec Downplays Threats From Competing HeartWare Pump

Thoratec’s virtual monopoly in the LVAD market is about to end with the anticipated launch of HeartWare’s system this month or next, but executives are not displaying major concern.

Dick Cheney Discusses Experience With HeartMate II Device

Thoratec’s miniature rotary blood pump LVAD is something Dick Cheney has “gotten used to living with,” the former U.S. vice president said Oct. 5 at the Cleveland Clinic’s annual Medical Innovations Summit in Cleveland, during an interview with ABC News anchor Bob Woodruff.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts